The director of melanoma research within the Northwestern Skin Cancer Institute presented his validation study at a meeting of the American Academy of Dermatology.
Scientists are working to determine if a specific receptor inhibitor could be used to augment chemotherapy or prevent relapse in individuals with the disease.